Latest filings (excl ownership)
DEFA14A
Additional proxy soliciting materials
26 Apr 24
DEF 14A
Definitive proxy
26 Apr 24
10-Q
2024 Q1
Quarterly report
25 Apr 24
8-K
Results of Operations and Financial Condition
25 Apr 24
10-K
2023 FY
Annual report
29 Feb 24
8-K
Results of Operations and Financial Condition
29 Feb 24
8-K
CHMP Issues Negative Opinion for Renewal of Conditional Marketing Authorization for Translarna™ (ataluren) Following Re-examination Procedure
25 Jan 24
8-K
Results of Operations and Financial Condition
8 Jan 24
POSASR
Automatic shelf registration (post-effective amendment)
7 Nov 23
10-Q
2023 Q3
Quarterly report
26 Oct 23
8-K
Results of Operations and Financial Condition
26 Oct 23
8-K
Termination of a Material Definitive Agreement
19 Oct 23
8-K
PTC Therapeutics Announces Evrysdi® Royalty Agreement with Royalty Pharma for Up To $1.5 Billion
19 Oct 23
8-K
PTC Announces Further Strategic Prioritization and Associated Reduction in Workforce
28 Sep 23
8-K
Other Events
22 Sep 23
8-K
CHMP Delivers Opinion on Translarna™ for Conversion to Full Authorization
15 Sep 23
10-Q
2023 Q2
Quarterly report
3 Aug 23
8-K
Results of Operations and Financial Condition
3 Aug 23
8-K
Regulation FD Disclosure
19 Jul 23
8-K
Departure of Directors or Certain Officers
17 Jul 23
8-K
Regulation FD Disclosure
21 Jun 23
8-K
Submission of Matters to a Vote of Security Holders
6 Jun 23
8-K
PTC Therapeutics Announces Strategic Pipeline Prioritization
23 May 23
8-K
PTC Therapeutics Announces APHENITY Trial Achieved Primary Endpoint with Sepiapterin in PKU Patients
17 May 23
D
$35.90 mm in equity / Common Stock, sold $35.90 mm, 40 investors
8 May 23
S-3ASR
Automatic shelf registration
5 May 23
POSASR
Automatic shelf registration (post-effective amendment)
28 Apr 23
10-Q
2023 Q1
Quarterly report
27 Apr 23
8-K
Results of Operations and Financial Condition
27 Apr 23
ARS
2022 FY
Annual report to shareholders
26 Apr 23
DEFA14A
Additional proxy soliciting materials
26 Apr 23
DEF 14A
Definitive proxy
26 Apr 23
8-K
Departure of Directors or Certain Officers
18 Apr 23
8-K
Departure of Directors or Certain Officers
24 Mar 23
10-K
2022 FY
Annual report
21 Feb 23
8-K
Results of Operations and Financial Condition
21 Feb 23
8-K
PTC Therapeutics Provides an Update on Commercial Progress and R&D Pipeline
9 Jan 23
S-8
Registration of securities for employees
16 Dec 22
S-3ASR
Automatic shelf registration
16 Dec 22
Latest ownership filings
4
Matthew B. Klein
22 Apr 24
4
Eric Pauwels
19 Apr 24
4
Matthew B. Klein
19 Apr 24
144
Notice of proposed sale of securities
19 Apr 24
144
Notice of proposed sale of securities
17 Apr 24
144
Notice of proposed sale of securities
17 Apr 24
4
Lee Scott Golden
4 Apr 24
144
Notice of proposed sale of securities
2 Apr 24
4
Christine Marie Utter
16 Feb 24
4
Neil Gregory Almstead
16 Feb 24
4
Eric Pauwels
16 Feb 24
4
MICHAEL SCHMERTZLER
16 Feb 24
4
William F. Jr. Bell
16 Feb 24
4
DAVID P SOUTHWELL
16 Feb 24
4
Stephanie Okey
16 Feb 24
4
Pierre Gravier
16 Feb 24
4
Lee Scott Golden
16 Feb 24
4
Matthew B. Klein
16 Feb 24
4
Mark Elliott Boulding
16 Feb 24
4
Emma Reeve
16 Feb 24
4
Allan Steven Jacobson
16 Feb 24
4
JEROME B ZELDIS
16 Feb 24
4
Alethia Young
16 Feb 24
4
GLENN JR MD PHD STEELE
16 Feb 24
4
Mary L. Smith
16 Feb 24
SC 13G
ARMISTICE CAPITAL, LLC
14 Feb 24
SC 13G/A
RTW INVESTMENTS, LP
14 Feb 24
SC 13G/A
VANGUARD GROUP INC
13 Feb 24
SC 13G/A
WELLINGTON MANAGEMENT GROUP LLP
8 Feb 24
4
Neil Gregory Almstead
1 Feb 24
4
Mark Elliott Boulding
1 Feb 24
4
Eric Pauwels
1 Feb 24
4
Christine Marie Utter
1 Feb 24
144
Notice of proposed sale of securities
30 Jan 24
144
Notice of proposed sale of securities
30 Jan 24
144
Notice of proposed sale of securities
30 Jan 24
144
Notice of proposed sale of securities
30 Jan 24
144
Notice of proposed sale of securities
30 Jan 24
4
Allan Steven Jacobson
24 Jan 24
SC 13G/A
STATE STREET CORP
24 Jan 24